

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	09/833,526
<b>Filing Date</b>	April 11, 2001
<b>First Named Inventor</b>	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, PHUONG N
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

Sheet	1	of	4
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner  
Signature

Date  
Considered

8/21/02

Examiner Signature	Phyllis J. [Signature]	Considered	7/2/01
--------------------	------------------------	------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Enter name of the inventor, as shown on the U.S. Patent Documents. 2 Enter name of the Office that issued the document, by the two-letter

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

number of the patent document. Kind of document is FF if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

8085 1449A.FRM (1/01) 1074806

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, PHUONG N
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

TECH CENTER 1600/2900

JUN 28 2002

RECEIVED

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T<sup>2</sup>

Examiner Initials*	Cite No. <sup>1</sup>		
Pst	C1	DOOMS, H. et al., "IL-2 and IL-15 direct the outcome of inappropriate CD4+ T cell stimulation towards apoptosis and anergy respectively," <i>European Cytokine Network</i> , 9(3):169 (1998)	
	C2	GRAY et al., "The Role of Transforming Growth Factor $\beta$ in the Generation of Suppression: an Interaction Between CD8 <sup>+</sup> T and NK Cells," <i>J Exp Med</i> 180:1937-1942 (1994)	
	C3	GRAY et al., "Generation of an Inhibitory Circuit Involving CD8 <sup>+</sup> T Cells, IL-2 and NK Cell-Derived TGF- $\beta$ : Contrasting Effects of Anti-CD2 and Anti-CD3," <i>J Immunol</i> , 160:2248-2254 (1998)	
	C4	AUCHINCLOSS, Hugh Jr., et al, in <i>Fundamental Immunology</i> 4th Ed., Paul, W.E. (ed.) Lippincot-Raven: Philadelphia, New York; 1999 pp. 1182-1222.	
	C5	BETZ, M. and FOX, B.S., "Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines," <i>J Immunol</i> . 1991 Jan 1;146(1):108-13.	
	C6	BUCY, R.P. et al., <i>FASEB J</i> . 1995 9:A497 (Abstract)	
	C7	COSIMI, A.B., et al., "Treatment of acute renal allograft rejection with OKT3 monoclonal antibody," <i>Transplantation</i> . 1981 Dec;32(6):535-9.	
	C8	GROUX, H., et al., "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," <i>Nature</i> . 1997 Oct 16;389(6652):737-42.	
	C9	JONULEIT, H., et al., "Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells," <i>J Exp Med</i> . 2000 Nov 6;192(9):1213-22.	
	C10	KIRK, A.D., et al., "CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates," <i>Proc Natl Acad Sci U S A</i> . 1997 Aug 5;94(16):8789-94.	
	C11	KOIDE, J. and ENGLEMAN, E.G., "Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones," <i>J Immunol</i> . 1990 Jan 1;144(1):32-40.	
	C12	LANCASTER, F., et al., "Anti-idiotypic T cells suppress rejection of renal allografts in rats," <i>Nature</i> . 1985 May 23-29;315(6017):336-7.	
	C13	LANGREHR, J.M., et al., "Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL," <i>Transplantation</i> . 1992 Mar;53(3):632-40.	
	C14	LARSEN, C.P., et al., "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," <i>Nature</i> . 1996 May 30;381(6581):434-8.	
	C15	MIZUOCHI, T., et al., "Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogeneic major histocompatibility antigens but not against trinitrophenyl-modified self," <i>J Exp Med</i> . 1985 Aug 1;162(2):427-43.	
	C16	PEARCE, N.W., et al., "Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. V. Dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2," <i>Transplantation</i> . 1993 Feb;55(2):374-80.	
✓	C17	PESCOVITZ, M.D., et al., "Effect of class II antigen matching on renal allograft survival in miniature swine," <i>J Exp Med</i> . 1984 Nov 1;160(5):1495-508.	

Examiner Signature	<i>Phyllis S...</i>	Date Considered	8/21/02
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

**Complete if Known**

Application Number 09/833,526  
Filing Date April 11, 2001  
First Named Inventor HORWITZ, David A.  
Group Art Unit 1644  
Examiner Name HUYNH, PHUONG N  
Attorney Docket Number A-68983-1/RFT/RMS/RMK

TECH CENTER 1600/2900

JUN 28 2002

RECEIVED

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PJH	C18	QIN, L., et al., "Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1," <i>Ann Surg.</i> 1994 Oct;220(4):508-18; discussion 518-9.	
	C19	QIN, L., et al., "Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival," <i>J Immunol.</i> 1996 Mar 15;156(6):2316-23.	
	C20	RAJU, G.P., et al., "Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats," <i>Transplantation.</i> 1994 Aug 15;58(3):392-6.	
	C21	RAMSDELL, F. and FOWLKES, B.J., "Maintenance of in vivo tolerance by persistence of antigen," <i>Science.</i> 1992 Aug 21;257(5073):1130-4.	
	C22	ROCHA, B., et al., "Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen," <i>J Exp Med.</i> 1993 May 1;177(5):1517-21.	
	C23	ROSER, B.J., "Cellular mechanisms in neonatal and adult tolerance," <i>Immunol Rev.</i> 1989 Feb;107:179-202.	
	C24	SAKAGUCHI, S., et al., "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases," <i>J Immunol.</i> 1995 Aug 1;155(3):1151-64.	
	C25	SEDDON, B. and MASON, D., "The third function of the thymus," <i>Immunol Today.</i> 2000 Feb;21(2):95-9.	
	C26	SHEVACH, E.M., "Regulatory T cells in autoimmunity," <i>Annu Rev Immunol.</i> 2000;18:423-49.	
	C27	SINGER, A., et al., "Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells," <i>J Exp Med.</i> 1981 May 1;153(5):1286-301.	
	C28	SNIJDEWINT, F.G., et al., "Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes," <i>J Immunol.</i> 1993 Jun 15;150(12):5321-9.	
	C29	STARZL, T.E., et al., "Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation," <i>Transplantation.</i> 1993 Jun;55(6):1272-7.	
	C30	TAAMS, L.S., et al., "Anergic T cells actively suppress T cell responses via the antigen-presenting cell," <i>Eur J Immunol.</i> 1998 Sep;28(9):2902-12.	
	C31	TOMITA, Y., et al., "Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?" <i>J Immunol.</i> 1990 Jan 15;144(2):463-73.	
	C32	VENDETTI, S., et al., "Anergic T cells inhibit the antigen-presenting function of dendritic cells," <i>J Immunol.</i> 2000 Aug 1;165(3):1175-81.	
✓	C33	VERBANAC, K.M., et al., "A role for transforming growth factor-beta in the veto mechanism in transplant tolerance," <i>Transplantation.</i> 1994 Mar 27;57(6):893-900.	

Examiner Signature

*Phy. A. S. S.*

Date Considered

8/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/833,526
		Filing Date	April 11, 2001
		First Named Inventor	HORWITZ, David A.
		Group Art Unit	1644
		Examiner Name	HUYNH, PHUONG N
Attorney Docket Number	A-68983-1/RFT/RMS/RMK		
Sheet	4	of	4

TECH CENTER 1600/2900  
JUN 28 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PJK	C34	WEKERLE, T., et al., "Anti-CD154 or CTLA4lg obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance," <i>Transplantation</i> . 1999 Nov 15;68(9):1348-55.	
	C35	WILSON, D.B., "Idiotypic regulation of T cells in graft-versus-host disease and autoimmunity," <i>Immunol Rev</i> . 1989 Feb;107:159-77.	
	C36	ZHENG, X.X., et al., "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," <i>J Immunol</i> . 1995 May 15;154(10):5590-600.	
	C37	PAWELEC, et al., "Cytokine Modulation of TH1/TH2 Phenotype Differentiation in Directly Alloresponsive CD4+ Human T Cells," <i>Transplantation</i> , 62(8):1095-1101 (October 1996).	
	C38	ZEHA VI-WILLNER et al., "The Mitogenic Activity of Staphylococcal Enterotoxin B (SEB): A Monovalent T Cell Mitogen That Stimulates Cytolytic T Lymphocytes but Cannot Mediate Their Lytic Interaction," <i>Journal of Immunology</i> 127(8):2682-2687 (1986)	
	C39	ZELLER et al., "Induction of CD4+ T Cell Alloantigen-Specific Hyporesponsiveness by IL-10 and TGF-β <sup>1</sup> , <i>Journal of Immunology</i> 163:3684-3691 (1999)	
	C40	HAN, et al., "A New Type of CD4+ Suppressor T cell Completely Prevents Spontaneous Autoimmune Diabetes and Recurrent Diabetes in Syngeneic Islet-Transplanted NOD Mice," <i>Journal of Autoimmunity</i> , 9:331-339 (1996)	
	C41	ROOK et al., "Effects of Transforming Growth Factor β on the Functions of Natural Killer Cells: Depressed Cytolytic Activity and Blunting of Interferon Responsiveness," <i>J Immunology</i> 136(10):3916-3920 (1986)	
	C42	ASAI O, et al., "Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation," <i>Journal of Clinical Investigation</i> 101(9):1835-1842 (1998)	
	C43	BOUSSIOTIS, "Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease," <i>Blood</i> 97:565-571 (Jan 2001)	
✓	C44	KOH et al., "Adoptive cellular immunotherapy: NK cells and bone marrow transplantation," <i>Histol Histopathol</i> 15:1201-1210 (2000)	

Examiner Signature		Date Considered	8/21/02
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.